Skip to main content

DEVELOP- A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

  • Aim: To evaluate the long-term safety and clinical status of pediatric patients with inflammatory bowel disease (IBD). Particular attention will be directed to recording safety outcomes reported in association with infliximab and other prescribed IBD therapies. Registry requiring questionnaires every 6 months and blood draw for patients on infliximab once a year
  • Eligibility: Children with ulcerative colitis and indeterminate colitis <17 years old with and without prior or current exposure to Infliximab 
  • More information: